Prolonged Therapy With Erythropoietin is Safe and Prevents Deterioration of Left Ventricular Systolic Function in a Porcine Model of Myocardial Infarction

Journal of Cardiac Failure

Volumn 16, Issue 7, 2010, Pages 579-589

  Angeli, Franca S ^a   Amabile, Nicolas ^a   Burjonroppa, Sukesh ^a   Shapiro, Mia ^a   Bartlett, Lauren ^b   Zhang, Yan ^a   Virmani, Renu ^b   Chatterjee, Kanu ^a   Boyle, Andrew ^a   Grossman, William ^a   Yeghiazarians, Yerem ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

cardiac remodeling; cytokine; Erythropoietin; myocardial infarction

Indexed keywords

AMIODARONE; ATENOLOL; C REACTIVE PROTEIN; D DIMER; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE REPERFUSION; MONONUCLEAR CELL; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; SWINE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77953691219     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.02.008     Document Type: Article

References (29)

1. Marzo F., Lavorgna A., Coluzzi G., Santucci E., Tarantino F., Rio T., et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thromb 26 (2008) 183-187
2. Lacombe C., and Mayeux P. Biology of erythropoietin. Haematologica 83 (1998) 724-732
3. Madonna R., Shelat H., Xue Q., Willerson J.T., De Caterina R., and Geng Y.J. Erythropoietin protects myocardin-expressing cardiac stem cells against cytotoxicity of tumor necrosis factor-alpha. Exp Cell Res 315 (2009) 2921-2928
4. Prunier F., Pfister O., Hadri L., Liang L., Del Monte F., Liao R., et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292 (2007) H522-H529
5. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28 (2007) 2018-2027
6. Rui T., Feng Q., Lei M., Peng T., Zhang J., Xu M., et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65 (2005) 719-727
7. Burger D., Lei M., Geoghegan-Morphet N., Lu X., Xenocostas A., and Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72 (2006) 51-59
8. van der Meer P., Lipsic E., Henning R.H., de Boer R.A., Suurmeijer A.J., van Veldhuisen D.J., et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 6 (2004) 853-859
9. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
10. Messina E., De Angelis L., Frati G., Morrone S., Chimenti S., Fiordaliso F., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95 (2004) 911-921
11. Brunner S., Winogradow J., Huber B.C., Zaruba M.M., Fischer R., David R., et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 23 (2009) 351-361
12. Sterin-Borda L., Barcelo A.C., and Bozzini C.E. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol 121 (2003) 180-186
13. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
14. van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
15. Gao E., Boucher M., Chuprun J.K., Zhou R.H., Eckhart A.D., and Koch W.J. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 293 (2007) H60-H68
16. Toma C., Letts D.P., Tanabe M., Gorcsan III J., and Counihan P.J. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 43 (2007) 130-136
17. Lipsic E., van der Meer P., Voors A.A., Westenbrink B.D., van den Heuvel A.F., de Boer H.C., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20 (2006) 135-141
18. Angeli F.S.S.M., Amabile N., Burjonroppa S., Orcino G., Zhang Y., Tacy T., et al. Left ventricular remodeling post-myocardial infarction: technical characterization of a swine model on beta-blocker therapy. Comp Med 59 (2009) 1-8
19. Powell J., and Gurk-Turner C. Darbepoetin alfa (Aranesp). Proc (Bayl Univ Med Cent) 15 (2002) 332-335
20. Lipsic E., Westenbrink B.D., van der Meer P., van der Harst P., Voors A.A., van Veldhuisen D.J., et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10 (2008) 22-29
21. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
22. Baan J., and Van der Velde E.T. Sensitivity of left ventricular end-systolic pressure-volume relation to type of loading intervention in dogs. Circ Res 62 (1988) 1247-1258
23. Glower D.D., Spratt J.A., Snow N.D., Kabas J.S., Davis J.W., Olsen C.O., et al. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 71 (1985) 994-1009
24. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
25. Apple K.A., Yarbrough W.M., Mukherjee R., Deschamps A.M., Escobar P.G., Mingoia J.T., et al. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol 47 (2006) 228-235
26. Sladek T., Sladkova J., Kolar F., Papousek F., Cicutti N., Korecky B., et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 31 (1996) 568-576
27. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32 (1998) 1486-1588
28. Kass D.A., and Maughan W.L. From 'Emax' to pressure-volume relations: a broader view. Circulation 77 (1988) 1203-1212
29. Fuchs S., Baffour R., Zhou Y.F., Shou M., Pierre A., Tio F.O., et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 37 (2001) 1726-1732